Amanda Glassman, director of global health policy and a senior fellow at the Center for Global Development (CGD), and Kate McQueston, a program coordinator at CGD, write in the center’s “Global Health Policy” blog that a reduction in AIDS funding to Ethiopia from PEPFAR and the Global Fund to Fight AIDS, Tuberculosis and Malaria “might be warranted due to epidemiological trends and improved efficiency, or might cripple progress as health programs dependent on external donors are cut back,” but “with the current poor status of basic information on beneficiaries and costs, it’s difficult to judge whether these cuts are good or bad.” They outline the history of AIDS funding in Ethiopia, posit what future funding might encompass, and say additional information is needed from PEPFAR, the Global Fund, and the Ethiopian government in order to know the true impacts of reduced funding (9/11).
The Global Fund to Fight AIDS, Tuberculosis and Malaria has published Issue 8 of its newsletter, the “Global Fund News Flash.” The issue reports on the Board’s approval of a new funding approach; says “the Board extended the mandate of the Global Fund to host the Affordable Medicines Facility-malaria for another year after the end of its pilot phase in December”; notes the Global Fund adopted a code of conduct for grant recipients; and profiles Linda Mafu, head of civil society and political advocacy at the Global Fund (9/20).
“In mid-July, … the near-final draft of the independent evaluation of the Affordable Medicines Facility — Malaria (AMFm) was released,” Victoria Fan, a research fellow at the Center for Global Development (CGD), and Heather Lanthorn, a doctoral candidate at Harvard School of Public Health, write in this post in the center’s “Global Health Policy” blog. “Never intended to be an experiment or quasi-experiment, the pre-post evaluation of the AMFm has so far been interpreted cautiously and optimistically; we’re encouraged by this,” they write. “But given that the evaluation considers trends in the outcomes of interest before and after AMFm in only the chosen AMFm countries, the evaluation lacks a counterfactual or comparison group,” they continue and detail the findings of the report. They conclude, “Regardless of what is decided for the next phase of AMFm, we strongly recommend that resources be allocated for, at a minimum, tracking outcomes more frequently and also in the non-AMFm countries” (9/4).
VOA News reports on a March 20 panel meeting in Washington, D.C., that highlighted the contributions of corporations and non-governmental organizations (NGOs) to the Global Fund to Fight AIDS, Tuberculosis and Malaria. Chevron, which has “invested $30 million for the three-year period between 2008 and 2011 and has pledged another $25 million through 2013,” was recognized at the meeting as “the first Global Fund Corporate Champion,” according to VOA (DeCapua, 3/23).
Gabriel Jaramillo, general manager of the Global Fund to Fight AIDS, Tuberculosis and Malaria, “has given an interview [.pdf] with the Spanish newspaper El Mundo, in which he outlines the direction and achievements to-date in making the Global Fund a more efficient and successful organization,” according to a Global Fund press release. In the interview, Jaramillo “also stresses the importance of continuing the work of the Global Fund in saving lives through greatly improving the grant management processes and strengthening this function inside the organization,” the press release states (3/28).
“At a public event [held Tuesday] on Capitol Hill, the Global Fund to Fight AIDS, Tuberculosis and Malaria and Friends of the Global Fight Against AIDS, Tuberculosis and Malaria spotlighted the contributions of public-private partnerships to the Global Fund’s lifesaving work,” a joint press release (.pdf) reports. The event highlighted the “unique and essential roles” that partners like Chevron, the Coca-Cola Company, (RED) and PEPFAR play in improving lives around the globe, “[f]rom assistance in drug delivery, to supplying much-needed resources, to mobilizing consumer markets, to in-country partnerships,” according to the press release. “The partners highlighted at the Capitol Hill event have not only provided funding, but have also brought their individual expertise to the Global Fund, sharing their knowledge and building bridges between the public, private and health sectors,” the press release states (3/20).
PlusNews examines challenges and concerns over an announcement by the Zimbabwean government that it plans to train nurses to prescribe and administer antiretroviral drugs (ARVs) to people living with HIV in the country. “Previously, nurses were allowed only to administer the drugs after a doctor had prescribed them,” the news service writes, adding, “Now, changes made in the job descriptions of nurses by the Nurses’ Council of Zimbabwe will see them prescribing the medication.” Owen Mugurungi, director of the HIV/AIDS and TB unit in the Ministry of Health and Child Welfare, said, “I need to point out that it’s not enough that a professional council allow nurses to administer drugs; this should be followed up with measures to capacitate nurses to do this work correctly,” according to PlusNews. The news agency looks at how the possibility of work overload for nurses, a government hiring freeze on nurses, and ARV availability could affect the country’s plan to reach 85 percent of the population in need of HIV treatment by the end of this year (10/16).
“Health workers in Myanmar are confident that efforts to narrow the country’s huge gap between access to, and need for, life-saving medicines to treat HIV/AIDS are back on track after the Global Fund to Fight AIDS, Tuberculosis and Malaria invited the country to apply for additional funding,” IRIN reports. “The agency’s coordinator for Myanmar, Eamonn Murphy, said new funds will allow the country to close a ‘treatment gap’ where only one-third of the 120,000 people nationwide who need [antiretrovirals (ARVs)] receive them,” the news service notes. “A spokesman for the Global Fund said it ‘had encouraged an application by the country for more money’ following an August visit to Myanmar by its general director,” IRIN writes. “Health officials drafted a ‘concept note’ outlining how additional funding might be used, which will be reviewed by the Global Fund’s board, Murphy said,” according to the news service, which notes, “It offers two scenarios: the first ensures 85 percent of those who need ARVs receive them by 2015; while with the second, 76 percent of people would be covered, he said.” The news service adds, “Based on feedback from the board, the government will choose a strategy for the proposal to be submitted early next year” (10/12).
Fareed Abdullah, CEO of the South African National AIDS Council (SANAC), who took office in July, spoke with PlusNews regarding the body’s reform, the revival of provincial AIDS councils, resource mobilization, and the appointment of a new board that allows SANAC to operate independently. According to the news service, Abdullah said the secretariat has three times as many staff as it did three months ago, adding, “We have a team of eight people working on the grant renewal process for about five Global Fund [to Fight AIDS, Tuberculosis and Malaria] grants. We’ve committed two staff members to dealing with PEPFAR [the U.S.-based President's Emergency Plan for AIDS Relief] and the new agreement to co-manage programs, and we’ll expand [staff] as the needs expand” (10/11).
Inter Press Service examines how Mexico’s government and non-governmental organizations are working to stem the spread of HIV among people who use injection drugs. “According to a project financed by the Global Fund to Fight AIDS, Tuberculosis and Malaria since 2011, the prevalence of HIV/AIDS in Mexico is 5.77 percent among intravenous drug users … compared to 0.24 to 0.3 percent in the general population aged 15 to 49,” IPS writes, noting HIV prevalence among drug users is highest in “northern Mexico, one of the areas in the country hit hardest by drug trafficking.” The news service adds “[t]here are 28 syringe exchange programs in this country of 112 million people, insufficient to serve the entire population of intravenous drug users.” IPS discusses funding shortfalls for syringe exchange programs, legal hurdles to obtaining clean injection equipment, and how the government aims to continue receiving Global Fund money through 2013 (Godoy, 10/11).